FINWIRES · TerminalLIVE
FINWIRES

HKG:2315

5 stories mentioning HKG:2315Updated 4d ago

Every FINWIRES story that references HKG:2315, newest first.

What's the latest news on HKG:2315?

Asia

Biocytogen Pharmaceuticals Adjusts Fundraising Project, Extends Timeline

Biocytogen Pharmaceuticals Beijing (SHA:688796, HKG:2315) raised the total investment for its drug early-stage research and development service platform construction project to 461.6 million yuan from 453.6 million yuan, according to a Thursday filing with the Shanghai bourse.The internal investment structure will shift, cutting construction engineering payment by 254.1 million yuan while adding 135 million yuan for decoration, 119.1 million yuan for equipment, and 8 million yuan for site leasing.The project completion date is extended to June 30, 2027, from Dec. 31, 2026.Shares of the pharmaceutical company rose 6% in recent trade on the Hong Kong bourse.

HKG:2315SHA:688796
Asia

Biocytogen Pharmaceuticals Beijing H1 Profit Jumps 402%; Shares Fall 3%

Biocytogen Pharmaceuticals Beijing (SHA:688796, HKG:2315) posted first-half attributable net profit of 241.1 million yuan, up 402% from 48.0 million yuan the previous year.Earnings per share rose to 0.54 yuan from 0.12 yuan, according to a filing with the Shanghai bourse.Operating revenue climbed 52% year over year to 941.4 million yuan from 621.0 million yuan.Shares of the pharmaceutical company fell 3% in recent trade on the Shanghai bourse and rose 2% in Hong Kong.

HKG:2315SHA:688796
Asia

Biocytogen Pharmaceuticals Expects H1 Profit to Soar by Up to 413%; Shares Up 10%

Biocytogen Pharmaceuticals Beijing (SHA:688796, HKG:2315) expects its net profit attributable to owners in the first half to surge by between 392% and 413% year on year to 236.1 million yuan to 246.1 million yuan, according to a Hong Kong bourse filing on Thursday.The Chinese pharmaceutical company's Shanghai shares jumped 10%, while Hong Kong shares rose 4% during the midday trade.The attributable profit a year earlier was almost 48 million yuan, with earnings per share of 0.12 yuan.Revenue is expected to jump by between 51% and 52% to 936.4 million yuan to a range of 936.4 million yuan to 946.4 million yuan from the year-ago revenue of 621 million yuan.

HKG:2315SHA:688796
Asia

Shanghai Court Dismisses HBM Subsidiary's Patent Infringement Claim Against Biocytogen

Biocytogen Pharmaceuticals (Beijing) (HKG:2315) scored a legal win in China after a court dismissed a claim made by HBM (HKG:2142) subsidiary Harbour Antibodies.Specifically, the Shanghai Intellectual Property Court made a first-instance judgment to dismiss Harbour Antibodies' allegation that Biocytogen's RenNano platform and related antibody products infringed on its exclusively licensed invention patent ZL201210057668.0, according to a Monday filing.

Shanghai Composite^SZSEHKG:2315
Asia

Biocytogen Pharmaceuticals Turns to Profit in Q1

Biocytogen Pharmaceuticals (Beijing) (HKG:2315) recorded an attributable profit of 104 million yuan in the first quarter of 2026, compared with an attributable loss of 13.2 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share stood at 0.23 yuan, compared with a loss per share of 0.03 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 74% in the three months to 433.1 million yuan from 249.3 million yuan in the year-ago period, driven by a substantially higher revenue contribution from pharmacology and efficacy services and animal models.The pharmaceutical company attributed the higher profit mainly to revenue growth and improved operating efficiency amid expense management.

HKG:2315

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2315 in your portfolio
WheelAI
WheelAI
Analyze HKG:2315 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2315